A method of diagnosing lung cancer in a subject-in-need thereof is provided. The method comprises: (a) providing a biological sample of the subject which comprises peripheral blood mononuclear cells (PBMCs); (b) in vitro contacting the PBMCs with a stimulant selected from the group consisting of the stimulants listed in Tables 3 and 4; and (c) measuring metabolic activity of the PBMCs having been contacted according to (b), wherein a statistically significant change in the metabolic activity of the PBMCs as compared to a control sample is indicative of lung cancer.

The treatment of diabetes mellitus with excellent hypoglycemic effect that suppresses lactic acidosis without substantially increasing the blood lactate concentration. A composition for treating diabetes mellitus with hypoglycemic effect that suppresses lactic acidosis without substantially increasing the blood lactate concentration, and the composition has branched-chain amino acids and salts of biguanide derivatives and derivatives of biguanide derivatives or branched-chain amino acids as the active components. The composition will be more effective when leucine, isoleucine, or valine is included as branched-chain amino acids, and metformin as the biguanide derivative.

The invention relates to the use in vitro of a kit for diagnostics, more particularly therapy-accompanying diagnostics, relating to a transplant and/or for diagnostics, more particularly therapy-accompanying diagnostics, relating to an autoimmune disease and/or for diagnostics, more particularly therapy-accompanying diagnostics, relating to a tumor disease and/or for diagnostics, more particularly therapy-accompanying diagnostics, relating to a vaccination, wherein the kit has the following components: a blood collection container, a blood collection set or blood collection system including a blood collection container, a nutrient medium for blood, and at least one activator for activating blood cells, more particularly immune cells, and/or at least one inhibitor for inhibiting blood cells, more particularly immune cells, and/or at least one modulator for modulating blood cells, more particularly immune cells.

The invention further relates to the use in vitro of a method for diagnostics in transplants and/or autoimmune diseases and/or tumor diseases and/or vaccinations, to a messenger-substance-containing supernatant for use in vitro in diagnostics in transplants and/or autoimmune diseases and/or tumor diseases and/or vaccinations, and to a combination for use in diagnostics in transplants and/or autoimmune diseases and/or tumor diseases and/or vaccinations.

A method of treating an asthmatic subject is provided. The method includes determining serum level of serum amyloid A (SAA) in the subject; comparing the serum level with a pre-determined threshold; and administering to the subject a therapeutically effective amount of a COX-2 inhibitor if the serum level is greater than or equal to the threshold.

Provided herein are methods and compositions related to Prevotella bacteria for the reduction of IL-8, IL-6, IL-Iβ, and/C or TNFα expression and/or for the treatment of viral infections.

Provided herein are agents, such as antibodies, antibody-drug conjugates, or chimeric antigen receptors, that target B7-H3. Methods of treating cancer are provided, comprising administering to a patient in need thereof an effective amount of an B7-H3-targeting agent. The patient may be selected for treatment if the cancer expresses an increased level of B7-H3.

The present invention relates to a biomarker composition for predicting the prognosis of a cancer patient, the biomarker composition including a first molecular subtype or a protein transcribed and translated from the first molecular subtype. The present invention also relates to a biomarker composition for predicting the prognosis of a cancer patient, the biomarker composition further including a second molecular subtype or a protein transcribed and translated from the second molecular subtype.

Described is a method for associating with the expression level of an AKR1C3 enzyme via the content of prostaglandin, and the use of screening for drug administration. In particular, the content of prostaglandin is measured to associate with the expression level of the AKR1C3 enzyme in a biological sample; and the change in the content and the change rate of the content of prostaglandin before and after administering interfering drugs are measured to associate with the expression level of the AKR1C3 enzyme in the biological sample.

The present invention relates to a pharmaceutical composition for inhibiting the resistance of liver cancer to sorafenib and enhancing an anticancer effect, comprising an Estrogen-related receptor γ (ERRγ) inhibitor as an active ingredient. The present invention can be effectively used as a pharmaceutical composition for treating sorafenib-resistant advanced liver cancer.

Methods for detection, diagnosis, prognosis, theragnosis, and targeted therapy of a PRSS21-overexpressing condition (e.g., cancer), in particular, PRSS21-overexpressing acute myeloid leukemia of the AMKL subtype.